Search
Methscopolamine bromide
go.drugbank.com/drugs/DB00462ApprovedA muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.
Friulimicin B
go.drugbank.com/drugs/DB06087InvestigationalFriulimicin B is a naturally occurring antibiotic produced by a micro-organism, *Actinoplanes friuliensis*.
ALTU-135
go.drugbank.com/drugs/DB05330InvestigationalALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA). … ALTU-135, the Company's orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug substance enzymes: lipase, protease and amylase
Mibefradil
go.drugbank.com/drugs/DB01388ApprovedWithdrawnMibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.
PRO 2000
go.drugbank.com/drugs/DB05385InvestigationalPRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials.
Delamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalDelamanid is approved by the EMA and is marketed under the trade name Deltyba as oral tablets. It is marketed by Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan).
Simoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedThe harvested product is concentrated and purified by a series of chromatography steps. … acids with an approximate molecular mass of 170 kDa, comprising the FVIII domains A1-A2 + A3-C1-C2 whereas the B-domain, present in the full-length plasma-derived FVIII, has been deleted and replaced by
Human interferon omega-1
go.drugbank.com/drugs/DB05472InvestigationalIt occurs naturally in the human body and is currently being manufactured by Intarcia through genetic engineering.
Tubercidin
go.drugbank.com/drugs/DB03172ExperimentalAn antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids
Umifenovir
go.drugbank.com/drugs/DB13609Investigational[A191475] Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational